Lobbying client · LD-2 disclosures
Nabi Biopharmaceuticals
Maryland
3 filings from 2 registrants · 2008–2010 · latest filed Apr 20, 2010
Reported on its behalf
$0
every LD-2 on file
Its own filed spend
$0
lobbying for itself
Fees to outside firms
$0
none reported
Spend over time
Every filing period on record, as reported. One column per filed period — a period with no column is a period with no filing, not a zero.
Basis · Amendments and terminations supersede the original report for the same registrant, client and period, so a revised quarter is counted once at its latest filed value. Registration-only filings carry no activity money and are excluded from these totals.
What they lobby on
Issue areas declared on the filings, ranked by how many filings name each one.
Budget/Appropriations
BUD
1 filing
Note · A filing names one to several issue areas and reports a single dollar figure for the period, so the same money appears beside every issue that filing declares. The dollar column is therefore spend on filings that named this issue — it is not a split of the total, and these figures sum above it. Filing counts do not double-count.
Who did the lobbying
Every lobbyist named on this client's filings.
- Christine M Warnke Hogan Lovells Cadwalader US LLP (Fka Hogan Lovells US LLP)1 filingthrough 2008
- C. Michael Gilliland Hogan Lovells Cadwalader US LLP (Fka Hogan Lovells US LLP)1 filingthrough 2008
The filings
Every filing on record. Each row links to its full disclosure.
This record groups every filed spelling of the client's name into one entity, so "MERCK & CO., INC." and "MERCK & CO INC" read as the same company. The grouping is the client's normalized name — organizations that file under genuinely different names appear separately. Handle: nabi-biopharmaceuticals.